<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363983</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A03330-57</org_study_id>
    <nct_id>NCT04363983</nct_id>
  </id_info>
  <brief_title>Interaction Between Host, Microenvironment and Immunity on Gastrointestinal Neoplasms</brief_title>
  <acronym>HoMING</acronym>
  <official_title>Interaction Between Host, Microenvironment and Immunity on Gastrointestinal Neoplasms: A Retro-prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective: association study of characteristics of tumoral microenvironment and
      immunity of digestive cancers with patients' overall survival (OS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to explore relationship between the molecular subgroups (DNA and RNA
      analysis), tumor microenvironment, host (immunity system, premetastatic niche, microbiota,
      metabolism) and survival (prognostic value), response (predictive value) and tolerance
      (toxicities) to conventional treatments or immunotherapies in digestive cancers, in
      particular, in colorectal cancer and pancreaticobiliary cancer.

      This is a prognostic monocentric study which includes 2 parts:

        -  one retrospective observational cohort for which 150 eligible patients (who have being
           diagnosed between 1998 to 2020) will be entered in the cohort per year during 22 years
           targeting 3300 patients and

        -  one prospective interventional cohort in which 3000 patients (diagnosis will be done
           between 2020-2030) will be enrolled during 10 years. 10 years of follow-up for all
           patients. This cohort is non comparative, non randomized, non control.

      The enrollment will last 10 years in Digestive Surgery Department, Ambroise Paré Hospital,
      APHP.

      There is any change in management of patients' care who will participate to the study, all of
      the treatment modalities (i.e. surgery, chemotherapy, radiotherapy, immunotherapy,
      intra-arterial treatments and supportive care) are possible and choice of treatment will be
      made by investigator physician, after multidisciplinary meeting validation, and according to
      referential and recommendations of practice in department.

      Statistic analysis

      The statistic analysis will be performed and reported according to the international
      guidelines STROBE for the observational studies.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">May 2030</completion_date>
  <primary_completion_date type="Anticipated">May 2030</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>monthly up to 3 months</time_frame>
    <description>The OS is defined as timeframe between beginning of treatment (date of surgery or 1st cure of chemotherapy/immunotherapy) and death (regardless of reason).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>yearly up to 10 years</time_frame>
    <description>The OS is defined as timeframe between beginning of treatment (date of surgery or 1st cure of chemotherapy/immunotherapy) and death (regardless of reason).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival without disease (SWD)</measure>
    <time_frame>at month 1, 2 and 3, then yearly up to 10 years</time_frame>
    <description>The SWD is defined as timeframe between date of surgical treatment and appearance of cancer relapse, 2nd cancer diagnosis or death (regardless reason).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without progression (SWP)</measure>
    <time_frame>at month 1, 2 and 3, then yearly up to 10 years</time_frame>
    <description>The SWP is defined as timeframe between the beginning of treatment (date of 1st cure of chemotherapy/immunotherapy or date of 1st session of radiotherapy) and the 1st progression or death (regardless reason).
The response of tumor will be evaluated according to the RECIST v1.1, Choi (intra-arterial treatments, antiangiogenic therapy) and/or iRECIST (immunotherapies) and/or imaging examinations depending on the given treatments.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">6300</enrollment>
  <condition>Gastrointestinal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Located/resected colorectal cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced colorectal cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Located/resected pancreatic cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced pancreatic cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Located/resected biliary tract cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced biliary tract cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Located/resected gastroesophageal cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced gastroesophageal cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Located/resected neuroendocrine cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced neuroendocrine cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood collection (50 ml) will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).
Following analysis should be performed with
serum for protein assays and characterization analysis of cytokines, new tumor markers and micro-RNA ...;
plasma for protein assays and characterization analysis of micro-RNA, VEC (the content of proteins, RNA, micro-RNA and DNA) and metabolomics;
PBMC for flow cytometry analysis, isolation macrophages;
whole blood for circulating tumor DNA (mutations by NGS, ddPCR,…; methylation) and circulating tumor cells.</description>
    <arm_group_label>Advanced biliary tract cancer</arm_group_label>
    <arm_group_label>Advanced colorectal cancer</arm_group_label>
    <arm_group_label>Advanced gastroesophageal cancer</arm_group_label>
    <arm_group_label>Advanced neuroendocrine cancer</arm_group_label>
    <arm_group_label>Advanced pancreatic cancer</arm_group_label>
    <arm_group_label>Located/resected biliary tract cancer</arm_group_label>
    <arm_group_label>Located/resected colorectal cancer</arm_group_label>
    <arm_group_label>Located/resected gastroesophageal cancer</arm_group_label>
    <arm_group_label>Located/resected neuroendocrine cancer</arm_group_label>
    <arm_group_label>Located/resected pancreatic cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver biopsy</intervention_name>
    <description>An intraoperative liver biopsy will be performed at free edge of liver with a triangular sample for local resected patients.
This biopsy will be done with scissors, then patients will receive intraoperative hemostasis with mono- or bipolar coagulation. This procedure will be under laparoscopy or laparotomy without extending standard processing time.
This biopsy seeks to allow the evaluate liver modifications testifying the preparing for premetastatic niche, which would allow to identify the patients with risk for hepatic relapsing; the same analysis on the tumors will be performed.</description>
    <arm_group_label>Located/resected biliary tract cancer</arm_group_label>
    <arm_group_label>Located/resected colorectal cancer</arm_group_label>
    <arm_group_label>Located/resected gastroesophageal cancer</arm_group_label>
    <arm_group_label>Located/resected neuroendocrine cancer</arm_group_label>
    <arm_group_label>Located/resected pancreatic cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stool collect</intervention_name>
    <description>Stool collection will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).
Analysis will be performed for microbiota and metabolism analysis.</description>
    <arm_group_label>Advanced biliary tract cancer</arm_group_label>
    <arm_group_label>Advanced colorectal cancer</arm_group_label>
    <arm_group_label>Advanced gastroesophageal cancer</arm_group_label>
    <arm_group_label>Advanced neuroendocrine cancer</arm_group_label>
    <arm_group_label>Advanced pancreatic cancer</arm_group_label>
    <arm_group_label>Located/resected biliary tract cancer</arm_group_label>
    <arm_group_label>Located/resected colorectal cancer</arm_group_label>
    <arm_group_label>Located/resected gastroesophageal cancer</arm_group_label>
    <arm_group_label>Located/resected neuroendocrine cancer</arm_group_label>
    <arm_group_label>Located/resected pancreatic cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Carcinoma of colorectal, pancreatic, biliary tract or gastro-oesophageal, or
             neuroendocrine digestive tumors with cytologically or histologically proven,
             regardless of the stage;

          -  Diagnosis between 1998 and 2030;

          -  Be &gt;/= 18 years;

          -  Have obtained signed informed consent (exemption for dead patients);

          -  Affiliated to the French social security - welfare system in France (CMU included).

        Exclusion Criteria:

          -  Patient under tutoraship or curatorship;

          -  Foreign patient under AME schema, a medical help from the state in France;

          -  Pregnant or breastfeeding women (for prospective study);

          -  Any clinical, psychological or social reason which should influence patient compliance
             with protocol, according to investigator;

          -  Patient refusal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédérique PESCHAUD, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Digestive Surgery Department, Ambroise Paré Hospital, APHP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cindy NEUZILLET, MD</last_name>
    <role>Study Director</role>
    <affiliation>Digestive Surgery Department, Ambroise Paré Hospital, APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédérique PESCHAUD, MD, PhD</last_name>
    <phone>+33 1 49 09 53 35</phone>
    <email>frederique.peschaud@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cindy NEUZILLET, MD</last_name>
    <phone>+33 1 47 11 15 15</phone>
    <email>cindy.neuzillet@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Digestive Surgery Department, Ambroise Paré Hospital, APHP</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastrointestinal cancer</keyword>
  <keyword>micro-environment</keyword>
  <keyword>immunity</keyword>
  <keyword>host</keyword>
  <keyword>microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

